DGAP-News: World Street Fundamentals: A Brighter Decade Ahead for Biotech – In-Depth Research Featuring GlaxoSmithKline and NPS Pharmaceuticals

DGAP-News: World Street Fundamentals / Key word(s): Study/Research
Update
World Street Fundamentals: A Brighter Decade Ahead for Biotech –
In-Depth Research Featuring GlaxoSmithKline and NPS Pharmaceuticals

15.04.2011 / 15:04

———————————————————————

A Brighter Decade Ahead for Biotech – In-Depth Research Featuring
GlaxoSmithKline and NPS Pharmaceuticals

Today, www.WorldStreetFundamentals.com released its industry report
highlighting GlaxoSmithKline (NYSE:GSK) and NPS Pharmaceuticals, Inc.
(NASDAQ:NPSP). Full fundamental and technical analysis is available at
www.WorldStreetFundamentals.com/Reports.php.

The global pharmaceutical market is expected to experience wide changes,
with trends growing towards the Asia-Pacific region. A favorable regulatory
environment has started to emerge in India, China, Malaysia, South Korea
and Indonesia; drawing the attention of larger API product providers. This
new competition within an already fast-paced economy has closed the gap
between product cost and disposable income of consumers- a change that is
expected to drive long-term growth within the global marketplace.

Global pharmaceutical market sales are expected to grow at a 4 – 7%
compound annual growth rate (CAGR) through 2013, largely driven via growing
access to health-care in emerging economic regions. Short-term growth
within the sector will be fueled by the US market, as it remains the
largest pharmaceutical market in the world. A large focus on R&D in
biotechnology, special drugs and generic drugs will remain a strong
catalyst to meet 2011 targets of $315 billion dollar in sales volume within
the United States alone.

World Street Fundamentals has highlighted GlaxoSmithKline for its recent
FDA approval of Horizant (gabapentin enacarbil) Extended-Release Tablets
for the treatment of moderate-to-severe primary Restless Legs Syndrome in
adults. It is the first medication in its class to be approved for the
treatment of moderate-to-severe primary Restless Legs Syndrome. Discovered
and developed by XenoPort, Horizant is a new chemical entity that utilizes
the body–s nutrient transport mechanisms that are believed to facilitate
its absorption into the body. The entire report on GlaxoSmithKline
(NYSE:GSK) is available here:
www.WorldStreetFundamentals.com/ViewFullReport.245.php.

World Street has highlighted NPS Pharmaceuticals for its focus on bringing
biopharmaceuticals to patients with rare disorders and few, if any,
therapeutic options. The company is advancing two Phase 3 registration
programs, GATTEX(R) (teduglutide) in short bowel syndrome (SBS) and NPSP558
(parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism.
NPS complements its proprietary programs with a royalty-based portfolio of
products and product candidates that includes agreements with Amgen, Kyowa
Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. The entire report on
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is available here:
www.WorldStreetFundamentals.com/ViewFullReport.138.php.

About World Street
World Street Fundamentals is an online portal for professionals, investors
and new-comers to the markets to find in depth comprehensive research and
research tools to help guide you through the ever changing financial
markets around the world.

Contact:

Adam Redford
editor@worldstreetfundamentals.com
www.WorldStreetFundamentals.com

End of Corporate News

———————————————————————

15.04.2011 Dissemination of a Corporate News, transmitted by DGAP – a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

———————————————————————

120215 15.04.2011